Charu Aggarwal, MD, MPH, discusses the optimal use of next-generation sequencing in molecular testing in non–small cell lung cancer.
Charu Aggarwal, MD, MPH, Leslye M. Heisler associate professor for lung cancer excellence, Perelman School of Medicine, University of Pennsylvania, discusses the optimal use of next-generation sequencing in molecular testing in non–small cell lung cancer (NSCLC).
Though tissue-based NGS remains the standard for molecular testing in NSCLC, tumors can now be sequenced through the minimally invasive plasma-based NGS, Aggarwal says. By utilizing both tissue-based and liquid-based NGS approaches, physicians can gain more from the testing, Aggarwal explains.
All patients with stage IV NSCLC, particularly those with a nonsquamous histology, must undergo NGS molecular testing, Aggarwal concludes.